Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18262805 | 0.94 | GAA (0.59) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL24507059 | 0.87 | GAA (0.71) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL1532004 | 0.85 | PPARG (0.45) | GAAALDH1A1CYP1A2CYP2C9PPARG | |
| SCHEMBL26480 | 0.85 | PPARG (0.45) | GAAALDH1A1CYP1A2CYP2C9PPARG | |
| SCHEMBL1532120 | 0.83 | PPARG (0.46) | GAAALDH1A1CYP1A2CYP2C9PPARG | |
| SCHEMBL12728222 | 0.82 | ALDH1A1 (0.51) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL12290505 | 0.82 | GAA (0.50) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL12244739 | 0.82 | GAA (0.61) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL14237856 | 0.81 | GAA (0.75) | GAAALDH1A1CYP1A2CYP2C9RECQL | |
| SCHEMBL29475643 | 0.81 | GAA (0.75) | GAAALDH1A1CYP1A2CYP2C9RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | AMBRX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3536700-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10093621-B2 | 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer | FONDAZIONE IRCCS INSTITUTO NAZIONALE DEI TUMORI (IT) | 2018-10-09 | — | — | US | disclosed |
| EP-3194360-B1 | 4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | FONDAZIONE IRCCS ISTITUTO NAZ DEI TUMORI (IT) | 2018-06-27 | — | — | EP | disclosed |
| US-9796754-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170253560-A1 | 4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (IT) | 2017-09-07 | — | — | US | disclosed |
| US-20170253560-A1 | 4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI (IT) | 2017-09-07 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-10093621-B2 | 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer | ALDH1A2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1 | GAA 4467/4885ALDH1A1 152/4885CYP1A2 2936/4885 |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | GAA 438/4885ALDH1A1 868/4885CYP1A2 2119/4885 |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | KLK3, PTMS, DDOST | GAA 557/4885ALDH1A1 2041/4885CYP1A2 3716/4885 |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | GAA 2037/4885ALDH1A1 4288/4885CYP1A2 4085/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | GAA 2037/4885ALDH1A1 4288/4885CYP1A2 4085/4885 |
| US-20170253560-A1 | 4-OXO-N-(4-HYDROXYPHENYL)RETINAMIDE DERIVATIVES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | ALDH1A2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RB1 | GAA 4467/4885ALDH1A1 152/4885CYP1A2 2936/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | GAA 529/4885ALDH1A1 1177/4885CYP1A2 2172/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | GAA 557/4885ALDH1A1 2041/4885CYP1A2 3716/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | GAA 557/4885ALDH1A1 2041/4885CYP1A2 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.